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Abstract
Lithium and antipsychotics are often prescribed to treat bipolar disorder or psychotic disorders in women of childbearing 
age. Little is known about the consequences of these medications during pregnancy for the developing child. The objective 
of this article is to systematically review findings from preclinical and clinical studies that have examined the neurodevelop-
mental consequences of intrauterine exposure to lithium and antipsychotics. A systematic search was performed in Embase, 
Medline, Web of Science, PsychINFO, Cochrane, and Google Scholar. Clinical and experimental studies were selected if 
they investigated neurodevelopment of offspring exposed to lithium or antipsychotics during gestation. Quality of clinical and 
preclinical studies was assessed by the Newcastle–Ottawa Scale and the SYRCLE’s risk of Bias tool, respectively. In total, 
73 studies were selected for qualitative synthesis and three studies were selected for quantitative synthesis. Of preclinical 
studies, 93% found one or more adverse effects of prenatal exposure to antipsychotics or lithium on neurodevelopment or 
behaviour. Only three clinical cohort studies have investigated the consequences of lithium exposure, all of which reported 
normal development. In 66% of clinical studies regarding antipsychotic exposure, a transient delay in neurodevelopment was 
observed. The relative risk for neuromotor deficits after in utero exposure to antipsychotics was estimated to be 1.63 (95% CI 
1.22–2.19; I2 = 0%). Preclinical studies suggest long-term adverse neurodevelopmental consequences of intrauterine exposure 
to either lithium or antipsychotics. However, there is a lack of high-quality clinical studies. Interpretation is difficult, since 
most studies have compared exposed children with their peers from the unaffected population, which did not allow correc-
tion for potential influences regarding genetic predisposition or parental psychiatric illness.
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Key points 
Preclinical studies suggest a harmful effect of lithium on motor activ-
ity, developmental milestones and reflexes, spatial memory and 
brain weight
Only three clinical cohort studies on the development of children 
with in utero exposure to lithium are published in the literature. 
They report normal development.
Most preclinical studies found a harmful effect of intrauterine expo-
sure to antipsychotics on motor activity, developmental milestones 
and reflexes and spatial memory
Clinical studies suggest a delay in motor functioning of children with 
in utero exposure to antipsychotics. In several studies, this delay 
appeared to be transient
Introduction
Patients with bipolar disorder or a psychotic disorder are 
often treated with lithium and/or antipsychotics in the acute 
phase of the disease and chronically for relapse prevention 
[1, 2]. As a substantial proportion of patients with bipolar 
disorder or a psychotic disorder are women of childbearing 
age, knowledge of the potentially deleterious consequences 
of intrauterine exposure to lithium and/or antipsychotics is 
critically important for optimally weighing the risks and 
benefits of different pharmacotherapy options. Continu-
ation of maintenance treatment during pregnancy is often 
necessary to maintain symptom stability and prevent relapse, 
while discontinuation of lithium or antipsychotics is associ-
ated with a higher relapse risk [3–5].
The teratogenic, obstetric and neurodevelopmental con-
sequences of intrauterine exposure to lithium and/or antip-
sychotics have remained poorly defined, largely due to the 
difficulty of implementing feasible study designs that avoid 
confounding by indication. Multiple studies have reported a 
positive association between intrauterine exposure to lithium 
and the risk of cardiovascular anomalies [6–10]. Lithium use 
during pregnancy has also been associated with an increased 
rate of miscarriages and preterm delivery [7, 9]. Similarly, 
antipsychotic use during pregnancy has been associated with 
higher rates of preterm delivery and low birth weight, as 
well as neonatal withdrawal symptoms, sedation and extrap-
yramidal side effects [11, 12]. However, severe mental ill-
ness, the indication for which lithium and antipsychotics are 
overwhelmingly prescribed during pregnancy, is also asso-
ciated with increased risk of obstetric and neonatal com-
plications independent of medication [13–15]. Therefore, 
confounding by indication has remained a challenging issue 
limiting the conclusiveness of previously observed associa-
tions between neonatal outcomes and medication exposure 
during pregnancy.
Further compounding the issue of study design, lit-
tle is known about the long-term neurodevelopmen-
tal consequences of intrauterine exposure to lithium or 
antipsychotics. It is widely assumed that the fetal environ-
ment influences lifetime disease risk based on Barker’s 
hypothesis of ‘fetal and infant origins of adult life’ [16, 17]. 
Following this reasoning, adverse fetal or neonatal conse-
quences of intrauterine exposure to lithium and/or antip-
sychotics might be expected to have neurodevelopmental 
consequences that extend well beyond infancy. Regard-
ing the cellular mechanisms of lithium, a neuroprotective 
effect is suggested through inhibition of glycogen synthase 
kinase-3 (GSK-3) [18, 19]. Mechanisms of antipsychotic 
action differ between the different types of antipsychotic 
medication with dopamine D2 receptor antagonism as the 
general pharmacodynamic property [20]. Several studies 
have suggested that atypical antipsychotics, but not typi-
cal antipsychotics, may also have neuroprotective effects 
[21]. Evidence from clinical neuroimaging studies in adults 
suggests that the use of lithium or antipsychotic medication 
can influence brain structure. Structural magnetic resonance 
imaging (MRI) studies have shown that lithium is associ-
ated with increases or normalization of gray matter volume 
in fronto-limbic brain structures [22], while antipsychotic 
medication has been associated with decreased brain volume 
and increased ventricular size [23]. Based on this informa-
tion one might expect similar, or even larger, effects when 
not the adult but the fetus is exposed during a crucial stage 
of neurodevelopment.
The objective of this article is to systematically review 
and synthesize findings drawn from both preclinical and 
clinical studies examining long-term neurodevelopmen-
tal outcomes following intrauterine exposure to lithium or 
antipsychotics, in an effort to gain further insight into the 
risks associated with the use of these medications during 
pregnancy.
Methods
Search strategy for systematic review
A systematic search was performed by a trained librarian 
in the following databases: (1) Embase, (2) MEDLINE, 
(3) Web of Science, (4) PsychINFO, (5) Cochrane, and (6) 
Google Scholar, from their respective inceptions through 
June 8, 2017 to identify studies that investigated the long-
term neurodevelopmental consequences of intrauterine 
exposure to lithium or antipsychotics. The search included 
the following elements: lithium, antipsychotics, (neuro) 
development and intrauterine exposure. All elements were 
transformed into a thesaurus suitable for each specific data-
base. The exact search terms per database are reported in the 
Supplementary material (Supplement 1).
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Study selection
Studies were considered eligible for inclusion if they were 
written in the English language and investigated the long-
term neurodevelopment, defined as neurodevelopment 
beyond the newborn period, of offspring exposed to lithium 
or antipsychotics during gestation. Experimental preclini-
cal investigations and clinical investigations were consid-
ered eligible for inclusion. Case reports were also included 
in this review. Two reviewers (EP and LS) independently 
screened the title and abstract of all records identified by 
our database search. Full text articles were obtained from 
the studies selected during this first screening step. Both 
reviewers independently selected the full text articles that 
met the eligibility criteria. The inclusion of both reviewers 
was compared and consensus was made on the final inclu-
sion. An additional search was performed on the reference 
section of relevant studies and review articles to screen for 
other eligible articles that were otherwise not identified by 
our structured search.
Data extraction
Two authors (EP and LS) independently extracted data on 
study design, sample size and characteristics, medication 
dosage and exposure period, follow-up time, and behav-
ioural, cognitive and neurological outcome measures. The 
data were summarized in a data extraction form. Studies 
were categorized by medication type and study design, and 
results were reported descriptively in accordance with the 
PRISMA statement [24].
Assessment of the risk of bias and the quality 
of studies
Methodological quality and risk of bias was assessed inde-
pendently for each study by two reviewers (EP and LS). 
Risk of bias in preclinical studies was assessed with the 
SYRCLE’s risk of Bias tool [25]. This tool was recently 
developed to assess risk of bias and has been adjusted for 
specific aspects of animal intervention studies. The Newcas-
tle–Ottawa Scale (NOS) [26] was used for clinical studies. 
The NOS assesses the risk of bias of observational studies 
based on selection, comparability and outcome criteria. The 
NOS rating scale varies from zero to nine; with zero rep-
resenting the highest risk of bias and nine the lowest risk.
Procedure for meta‑analysis
For our meta-analysis, we used the same search strategy as 
mentioned before. Only clinical investigations were included 
in the meta-analysis with the goal to enhance further insight 
into the risks associated with the use of these medications 
during pregnancy in humans. Pooling was performed per 
type of neuropsychological outcome and per group of medi-
cation exposure (lithium or antipsychotics) over a minimum 
of two studies. Fixed and random-effect estimation was used. 
In case of substantial heterogeneity, a random-effect esti-
mation provides more reliable pooled results. Results are 
plotted in a forest plot. Cochran’s Q test, and I2 statistics 
were used to quantify heterogeneity across trials. I2 >40% 
was considered as substantial heterogeneity. The influence 
of intrauterine exposure to lithium or antipsychotics on neu-
ropsychological development over time was estimated using 
random effects meta-regression analysis. Statistical analyses 
were performed using the ‘Metan package’ in Stata 15 [27].
Results
Study selection
The study selection process is presented in Fig. 1. Our initial 
search produced a total of 1985 articles. After duplicates 
were removed, 1427 articles remained. Based on the screen-
ing of title and abstract, 182 full text articles were exam-
ined for eligibility, of which 118 were excluded (Fig. 1). In 
total, 73 studies were included in the qualitative synthesis, 
of which nine studies were included through manual (non-
structured) identification. Additionally, three studies were 
included in the quantitative synthesis.
Study characteristics
The characteristics and results of the preclinical investiga-
tions included in the qualitative analysis are summarised in 
Table 1 and 2. The characteristics and results of the clinical 
studies can be found in Table 3 and 4. Table 1 and 2 in the 
Supplementary Material (Supplement 2) present the charac-
teristics and results of case reports.   
Of the 73 studies included in the qualitative analysis, 29 
were preclinical investigations of which seven examined 
lithium exposure and 22 examined antipsychotics exposure. 
Most preclinical studies were performed in rats, some in 
mice and one study on lithium exposure used zebrafish. 
There is a large variety of the measurements used to assess 
neurodevelopment in animal models (Table  1, 2). The 
exposed period was generally during gestation, although 
several studies also investigated the effect of exposure dur-
ing lactation. Postnatal brain development in rodents up to 
postnatal day 10 is considered analogous to prenatal brain 
development in humans [28].
In total, we found 13 clinical cohort studies of which three 
involved lithium exposure and ten involved antipsychotics 
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exposure (Table 3, 4). Study samples varied from 14 to 2141 
exposed subjects. Mean follow-up duration ranged from 1 
to 15 years in studies involving lithium exposure and from 
14 days to 5 years in studies involving antipsychotic expo-
sure. Assessment of neurodevelopment varied between 
cohort studies. Out of the three clinical studies involv-
ing lithium exposure, one used standardized assessments, 
while the other two relied on an invalidated questionnaire 
or telephone interview. Most studies involving antipsychotic 
exposure used standardized objective assessments, but some 
studies relied solely on invalidated questionnaires or inter-
view. Additionally, 31 case studies were included, of which 
5 involved intrauterine lithium exposure and 26 involved 
intrauterine antipsychotics exposure (Supplement 2).
Lithium
Preclinical investigations
Sechzer et al. [29] investigated the long-term developmen-
tal consequences of prenatal and early postnatal lithium 
exposure in rats. Female rats were treated with lithium dur-
ing pregnancy and lactation. Development of the startle 
response and depth perception in the offspring were delayed. 
At the age of 4 months, pups exhibited lower spontaneous 
activity during open field activity testing. A similar study 
investigated the neurodevelopmental effect of lithium expo-
sure from day 1 of pregnancy until postnatal day 15 [30]. 
Decreased locomotor activity and delayed development of 
sensory motor reflexes were observed in lithium-exposed 
mice. Whether these developmental delays were caused 
by prenatal or early postnatal exposure to lithium could 
not be determined. Nery et al. [31] studied the behavioural 
effects of lithium exposure on the development of zebrafish 
embryos and reported decreased locomotion compared to 
non-exposed embryos. Additionally, several studies have 
replicated a delay in eye opening [29, 30, 32] and decreased 
avoidance behaviour [32, 33] in mice and rats exposed to 
lithium during gestation and/or lactation. One study found 
impaired performance on the T-maze test [33]. Messiha 
et al. [34] found lower brain weights in lithium exposed off-
spring at the age of 37 days. No changes in social, defensive, 
threatening or aggressive behaviour was observed in lithium-
exposed mice [35].
In summary, preclinical studies suggest a deleterious 
effect of lithium on motor activity, developmental milestones 
and reflexes, spatial memory and brain weight.
Manual inclusion
(idenficaon
through reviews): 
n= 9
Records screened: 
n= 1427
Full-text arcles assessed for
eligibility: 
n= 182
Records excluded: 
n= 1245
Studies included in qualitave synthesis: 
n= 73
Full-text arcles excluded: 
n= 118
o Outcome not neurodevelopment 
(n=38)a
o Reviews, guidelines (n=24)
o Conference abstracts (n=19)
o Exposure not during gestaon (n=13)
o No lithium or anpsychoc
exposure(n=11)
o Language not English (n=11)
o Book chapter (n=2)
Records idenfied through
database searching
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Fig. 1  Flowchart of the study selection process in this systematic 
review and meta-analysis. aOutcome of the excluded studies: cell devel-
opment (n = 4), teratogenicity (n = 5), neonatal outcome only (n = 14), 
obstetric outcome and teratogenicity (n = 9), fetal development (n = 2), 
endocrine and cardiologic follow-up (n = 1), weight gain and mortality 
(n = 1), treatment choice (n = 1), sexual development (n = 1)
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Clinical investigations
Neurodevelopment of 97 children with in utero exposure 
to lithium has been investigated in clinical cohort studies. 
Overall, most children were reported to have typical neu-
rodevelopmental trajectories. Schou analysed data from 
the Scandinavian Register of Lithium Babies to compare 
neurodevelopmental outcomes in lithium-exposed children 
(n = 60) with their non-exposed siblings (n = 57) (average 
age, 7 years) [36]. Outcomes were assessed by question-
naire and based solely on mothers’ subjective retrospective 
assessment of their children’s developmental milestones. No 
significant differences were observed between the lithium-
exposed children and their siblings.
In a prospective multicenter study, major developmental 
milestones were examined between a sample of 22 lithium-
exposed children with non-exposed children [37]. Subjects 
were screened for study inclusion from among mothers who 
contacted the public teratogen information services to dis-
cuss the potential risks of prescription medication use during 
pregnancy. Data were collected by telephone interview. No 
differences were observed between lithium-exposed versus 
non-exposed children in the age at which they achieved 
major developmental milestones.
In an observational cohort study, 15 lithium-exposed 
children between 3 and 15 years old were investigated [38]. 
Standardized validated tests were used to assess growth, 
neurological, cognitive and behavioural outcomes. When 
compared to norms from the general population, most 
lithium-exposed children scored lower on the Block pat-
terns subtest of the Wechsler Intelligence Scale for Chil-
dren (WISC-III-NL). In contrast, no differences in growth 
or behavioural outcomes were observed. One child in this 
study exhibited subclinical neurological findings. Impor-
tantly, however, the conclusiveness of this study was ham-
pered by the lack of a matched non-exposed control group 
ascertained in parallel with the lithium-exposed group, but 
rather relied upon an independently collected general popu-
lation cohort dataset.
In summary, there is a paucity of clinical data on the 
neurodevelopment of children with in utero exposure to 
lithium. The three clinical studies published in the litera-
ture report normal neurodevelopment.
Case reports
Neurodevelopmental delay after intrauterine exposure to 
lithium was reported in four case studies, encompassing a 
total of eight children [39–42]. Kozma et al. [39] reported 
on a neonate with neurodevelopmental deficits, including 
decreased muscle tone, depressed reflexes and diminished 
social response, during the 2.5 months after birth. How-
ever, by 13 months of age, no deficits were observed using 
Table 3  Characteristics of clinical studies on neurodevelopmental outcome after intrauterine exposure to lithium
n.r. not reported, BSID Bayley Scale of Infant Development, WPPSI Wechsler Preschool and Primary Scale of Intelligence, WISC Wechsler 
Intelligence Scale for Children, MND minor neurologic dysfunction; NOS: Newcastle–Ottawa Scale
a parent report
Author (year) Study design Sample size Lithium daily 
dosage
Treatment 
indication
Follow-up time Measurements Results NOS
Schou (1976) 
[36]
Prospective 
cohort study
Exposed = 60
Controls = 57
n.r. n.r. Mean: 7 years Developmental 
 questionnairea
No difference 
in rate of 
abnormal 
development
7
Jacobson 
(1992) [37]
Prospective 
cohort study
Exposed = 22
Controls = n.r.
Mean: 927 mg Major affective 
disorders
Mean: 
61 weeks, 
range: 
1-9 years
Telephone inter-
view on the 
attainment of 
developmental 
milestones
No difference 3
vd Lugt (2012) 
[38]
Cohort study Exposed = 15
No controls
n.r. Bipolar dis-
order
3–15 years Development 
 questionnairea
IQ by BSID or 
WPPSI/WISC
Hempel or 
Touwen 
neurological 
examination
Child Behavior 
Checklist*
MND (n = 1).
Low V–
IQ + T–IQ 
normal P–IQ 
(n = 1)
Subclinical 
anxiety prob-
lems (n = 2).
Subclinical 
oppositional 
problems 
(n = 1)
6
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the Bayley Scale of Infant Development. Morrel et al. [43] 
described a case of lithium toxicity at 35 weeks of gesta-
tion (lithium blood level: 2.6 mmol/L). The baby was born 
with primary cardiac muscle dysfunction and treated with 
isoprenaline at birth. At 12 months of age, cardiac function 
had normalized but there was evidence of delayed motor 
development and a concomitant strabismus. Delayed gross 
motor function was also reported in two cases with prena-
tal lithium exposure that did not involve lithium intoxica-
tion [41, 42]. One case report reported normal psychomo-
tor development [44].
Antipsychotics
Preclinical investigations
Eleven studies have investigated the long-term neurodevel-
opmental consequences of prenatal haloperidol exposure 
in rats. Emergence of the surface righting reflex was found 
to be delayed [45]. Two studies found deficits in a circling 
training test [45, 46], a measure of motor performance 
and associative learning. Impairments in spatial learning 
were also found [45, 47, 48] using the Morris water maze, 
T-maze and radial arm maze. Moreover, the open field test 
revealed increased rearing, ambulation and general activ-
ity [47, 49–51]. One study reported finding no difference 
in ambulation on the open field test [52]. Notably, since 
behaviour in the open field test is influenced not only by 
locomotor activity, but also by anxiety and exploratory 
behaviour [53], additional studies have been performed 
to further differentiate these phenotypes. Indeed, consist-
ent with an increase in anxiety, rats made fewer entries 
and spent less time in open arms during elevated zero and 
plus-maze tests [49, 51]. Moreover, aggressive behaviour 
was also increased [54]. Duration of shock-precipitated 
wall climbing was reduced on postnatal days 9 and 11, and 
there were no differences in stimulant induced behavioural 
stereotypes [55]. Lastly, from a neuroanatomical perspec-
tive, rats with intrauterine exposure to haloperidol exhib-
ited significantly lower brain weight in adulthood [56].
Eight studies have investigated the long-term neurode-
velopmental effects of intrauterine exposure to chlorprom-
azine in rats. One study systematically investigated the 
onset of neurodevelopmental milestones [57]. They found 
no difference in onset of eye opening, but emergence of the 
righting reflex was delayed. Studies investigating motor 
development found both increases [58] and decreases [59] 
in wheel running activity and impairments in a hanging 
task [57]. In the open field test, latency time was decreased 
[59, 60] and locomotor activity was increased [60, 61]. 
Similarly, spontaneous activity was normal in one study 
[62], but decreased in another [63]. Spatial memory was 
found to be impaired in a mother-goal maze task, whereas 
no differences were found in a T-maze task [61]. Studies 
focusing on other types of learning have reported impaired 
avoidance conditioning [57, 59], reversal learning [62] 
and operant conditioning [61]. Avoidance conditioning 
was observed to be normal [64]. A study investigating 
exploratory behaviour found that rats made fewer hole 
dippings [64]. Hoffeld et al. [58] did not find changes in 
emotionality testing. Susceptibility to audiogenic seizures 
was increased [63]. Brain weights did not differ between 
chlorpromazine and placebo exposed groups [60].
Several other antipsychotics were examined for neurode-
velopmental effects. Rosengarten et al. [65] investigated the 
possible sequelae of intrauterine exposure to quetiapine, 
risperidone or olanzapine and found impaired spatial learn-
ing in a radial arm maze task for both risperidone and que-
tiapine, and disrupted short-term retention for quetiapine. 
Intrauterine exposure to olanzapine did not affect learning 
or retention. A recently published study also found impaired 
spatial learning and retention capability in rats with prenatal 
exposure to quetiapine [66]. Two studies investigated the 
effects of risperidone exposure during gestation. Singh et al. 
[67] reported increased ambulation and rearing in the open 
field test, and increased anxiety-like exploratory behavior 
in the elevated plus maze test. Intrauterine exposure to ris-
peridone led to a dose-dependent reduction of adult brain 
weight. Zuo et al. [68] also found increased ambulation, 
while righting reflexes and spatial memory were normal. 
In the same study, rats with prenatal exposure to sulpiride 
exhibited an impaired cue response in a visual task perfor-
mance and reduced spontaneous activity, while righting 
reflexes and spatial memory were normal.
In summary, most preclinical studies found a deleteri-
ous effect of antipsychotics on motor activity, developmen-
tal milestones and reflexes and spatial memory. Addition-
ally, exposure to either haloperidol or risperidone led to 
decreased brain weight.
Clinical investigations
In total, neurodevelopmental data of 2934 children with in 
utero exposure to antipsychotics have been published involv-
ing nine clinical cohort studies. Six studies reported neu-
rodevelopmental delays or deficits after prenatal exposure to 
antipsychotics [69–74], while three studies reported normal 
developmental outcomes [75–77]. Most studies reported 
antipsychotic exposure on the basis of a single broad cat-
egory, which combined a wide variety of antipsychotics. 
The initial report of abnormalities of motor development 
in children with intrauterine exposure to antipsychotic was 
authored by Platt in a cohort of 192 children exposed to 
antipsychotic neuroleptics and 116 children of women with 
a history of psychiatric disorders described as psychotic/
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neurotic but without antipsychotic treatment. Notably, defi-
cits at the neonatal assessment of motor activity were more 
severe than at 8 months of age, when there was a non-signif-
icant trend towards more failures based on the Bayley gross 
motor assessment [73]. Another study examined 21 children 
with prenatal antipsychotic exposure, 183 children with pre-
natal antidepressant exposure and 78 non-exposed children 
at 6 months of age [78]. Children with prenatal exposure to 
antipsychotics had lower scores on the infant neurological 
international battery (INFANIB) compared to children with 
prenatal antidepressant exposure or non-exposed children. 
Comparable results were found in a recent register-based 
study in France [74]. Psychomotor development, assessed 
by pediatric examination, was compared between 70 chil-
dren with prenatal neuroleptic exposure and 32.303 non-
exposed controls. A higher prevalence of motor deficits was 
reported in exposed children at 9 months of age, a difference 
that was no longer present at 24 months of age. No differ-
ences in cognitive development were observed. A Danish 
general population register-based study reported an asso-
ciation between drug prescriptions during pregnancy and 
results on the Boel test, a psychomotor development test 
assessed at 7–10 months of age [71]. Specifically, the odds 
ratio for an abnormal Boel test was 4.1 (95% CI 1.3–13.0) 
among children with intrauterine exposure to neuroleptic 
medication after adjustment for several confounders includ-
ing gestational age, birth weight and breastfeeding. In con-
trast, Stika et al. [76] reported finding no discernible adverse 
behavioural outcomes based on evaluations made by their 
classroom teachers in 10-year-old children with prenatal 
neuroleptic exposure.
Using data from two large electronic primary care data-
bases in the UK, Petersen et al. investigated the risks and 
benefits of psychotropic medication during pregnancy. 
They compared the prevalence of neurodevelopmental and 
behavioural disorders in children with prenatal exposure 
to antipsychotics, children with no antipsychotic exposure 
whose mothers discontinued antipsychotic treatment before 
pregnancy and non-exposed children whose mother was not 
prescribed antipsychotic treatment in the 24 months before 
pregnancy. They found an increased risk of neurodevel-
opmental and behavioural disorders in children exposed 
to antipsychotics with a relative risk ratio (RRR) of 1.58 
(95% CI 1.04–2.40). However, after adjustment for possible 
confounders, these differences were no longer statistically 
significant (RRR 1.22, 95% CI 0.80–1.84) [75]. An earlier 
study, focused specifically on phenothiazine antipsychot-
ics, similarly reported no difference in intelligence quotient 
scores among 4-year-old children, of which 2141 had pre-
natal exposure and 26,217 were non-exposed [77]. Notably, 
however, a higher burden of neonatal withdrawal symptoms 
and autonomic instability was reported 14 days after birth in 
neonates with intrauterine exposure to phenothiazine antip-
sychotics [69].
More recent studies have also focused on the long-term 
developmental consequences of intrauterine exposure to 
atypical antipsychotics. Peng et al. [79] prospectively inves-
tigated 76 children with intrauterine exposure to atypical 
antipsychotics and 76 non-exposed controls, from birth 
until 12 months of age. Neurobehavioural development was 
assessed by the Bayley Scale of Infant and Toddler Develop-
ment (BSID) at 2, 6 and 12 months of age. At 2 months of 
age, antipsychotic-exposed children exhibited significantly 
lower scores regarding cognitive, motor, social-emotional, 
and adaptive behavioural functioning. At 6 months of age, 
scores regarding social-emotional and adaptive behavioural 
functioning were still lower, but not significantly different 
between groups in cognitive or motor scores. In contrast, by 
12 months of age none of these effects persisted. A post hoc 
analysis revealed that children prenatally exposed to clozap-
ine had lower scores on the BSID adaptive behavior scale at 
the ages of 2 and 6 months compared to children exposed to 
other atypical antipsychotics [80]. However, this difference 
was also no longer present at 12 months of age.
Although studies varied in measurements and follow-
up time, five cohort studies [70–74, 80] investigated motor 
development of children with in utero exposure to antipsy-
chotics. These studies consistently showed a deficit in motor 
functioning in the first 9 months of life, but which appeared 
to spontaneously resolve based on subsequent follow-up 
assessments.
Case reports
Overall, case studies on intrauterine exposure to first gen-
eration antipsychotics have largely reported normal neu-
rodevelopment [81–88]. Additionally, although most case 
studies involving prenatal exposure to second generation 
antipsychotics have also reported normal infant and child 
development [81, 88–101], several case reports have found 
neurodevelopmental delays or deficits. Two cases reported 
speech delay, one involving risperidone and the other clo-
zapine [102, 103]. One case reported abnormal behavioral 
development following prenatal exposure to risperidone and 
ziprasidone [103]. Impaired motor development has been 
reported following exposure to olanzapine, clozapine or ris-
peridone [104–106].
Risk of bias and quality of the included studies
The risk of bias for the included preclinical studies is pre-
sented in the Supplementary Material (Supplement 3). Nota-
bly, many lack descriptions of the assessed domains, thereby 
making the risk of bias unclear (e.g., selection bias, perfor-
mance bias, detection bias or attrition bias). In 34% of the 
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preclinical studies, cross-fostering after birth was applied in 
order to control for medication-induced changes in maternal 
care.
NOS scores of clinical cohort studies varied between 
three and eight points (Table 3 and 4). Only three cohort 
studies properly controlled for maternal mental illness, 
widely considered the most important confounder in stud-
ies of intrauterine exposure to prescription psychotropic 
medication. In the other studies, neurodevelopment was 
compared between children with prenatal exposure to lith-
ium or antipsychotics versus unaffected children, thereby 
leaving unaddressed the risk of confounding by indication. 
Moreover, few clinical studies controlled for additional con-
founders such as maternal age, congenital malformations, 
preterm birth, or smoking and alcohol use during pregnancy, 
often because information on these factors was not available. 
In most studies of antipsychotic exposure, developmental 
assessments were standardized and validated, although some 
studies based their results on non-validated questionnaires 
or information obtained exclusively from medical records. 
The quality of the included studies on lithium exposure is 
poor, as only one cohort study used validated measurements 
of neurodevelopment. Unfortunately, this study did not com-
pare their findings with a formal control group. Regarding 
case studies, their quality is generally considered low with 
a high risk of publication bias. Indeed, most case studies 
did not assess neurodevelopment using validated objective 
measures.
Meta‑analysis
Three out of five studies that investigated neuromotor defi-
cits in children with in utero exposure to antipsychotics pro-
vided sufficient data and were included in a meta-analysis 
[70, 72, 74]. Figure 2 shows the relative risk of neuromotor 
deficits for antipsychotic exposure for all reported follow-up 
assessments (six effect sizes). Pooled relative risk calculated 
using fixed effect estimation was 1.97 (95%CI 1.47–2.62; Z 
value: 4.59, p < 0.001) with absence of heterogeneity (I2 0%, 
p = 0.622). Since studies reported multiple follow-up out-
comes, this pooled estimate should be interpreted with care.
Two studies [70, 72] reported follow-up outcomes 
at 6 months. The pooled relative risk was 1.63 (95% CI 
1.22–2.19; Z value = 3.29; p = 0.001, fixed effect) with 
absence of heterogeneity (I2 = 0%, p = 0.849), indicating 
a 63% increased risk for neuromotor deficits at 6 months 
(Fig. 3).
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Next we performed a random effects meta-regression 
analysis to study the longitudinal influence of intrauterine 
exposure to antipsychotics on motor development. For each 
study, we included the initial follow-up assessment. The 
direction of the regression coefficient suggested a decrease 
of the impact of intrauterine exposure to antipsychotics on 
neuromotor deficits over time. However, there was no sta-
tistically significant effect (− 0.03; 95% CI − 1.26 to 1.20; 
p = 0.80). Residual heterogeneity was substantial (I2 = 49%). 
In conclusion, in this meta-analysis we were able to partially 
confirm the negative effect of antipsychotic exposure on 
motor development. However, we were not able to confirm 
the transient nature of the neuromotor deficits.
Discussion
In this systematic review article and meta-analysis, we pre-
sent an overview of the current literature regarding long-
term neurodevelopmental effects of lithium and antipsy-
chotics. Towards this goal, we included both preclinical 
and clinical studies. Preclinical studies have the potential 
to investigate the effect of medication exposure using more 
optimal study designs in which important biases in clinical 
studies, such as confounding by indication, can be directly 
addressed. Notably, although preclinical findings may not 
always be translatable into clinical practice, they have the 
potential to provide mechanistic insights and reveal indica-
tions of possible risks in situations for which well-controlled 
high-quality clinical studies are lacking. Undoubtedly, 
however, disproportionate weight should be given to evi-
dence discerned from relevant clinical studies when helping 
women to consider the risks and benefits of their perinatal 
treatment options.
Overall, findings from preclinical studies suggest a del-
eterious effect of lithium on locomotor activity and delayed 
development of eye opening and righting reflexes. Addition-
ally, brain weight was found to be lower in lithium-exposed 
offspring. Clinical studies of offspring neurodevelopment 
after intrauterine exposure to lithium generally reported 
normal development. However, two out of the three stud-
ies based their results exclusively on retrospective mater-
nal reports, while the third study lacked a formal control 
group. The lack of clinical studies on the risks of lithium 
use during pregnancy might be due to the fact that lithium 
is a naturally occurring element that was never patented. 
Another explanation for the knowledge gap on long-term 
neurodevelopmental effects of lithium exposure might be 
the (earlier recognized) association with cardiac malforma-
tions. This association was first reported in the 1970′s by 
Schou et al. and a recent study by Patorno et al. confirmed 
this association although the authors report that the risk was 
lower than previously suggested [10, 107]. These findings 
have influenced treatment guidelines in the United Stated 
Overall  (I-squared = 0.0%, p = 0.849)
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and the United Kingdom, where lithium use during preg-
nancy is discouraged [108, 109], and possibly also influ-
enced research to focus on congenital malformations rather 
than on neurodevelopment.
Despite the many differences in methodology, preclinical 
studies consistently reported adverse neurodevelopmental 
and behavioural effects of prenatal exposure to antipsychot-
ics. Antipsychotics seem to increase locomotor activity and 
anxiety, as well as impair cognition, in exposed offspring. 
Lastly, and of important consideration for clinical transla-
tional potential, brain weight was found to be lower in off-
spring with intrauterine exposure to haloperidol and risperi-
done. Most studies of antipsychotics involved haloperidol 
and chlorpromazine, while a much smaller number focused 
on varied atypical antipsychotics. At present, there is insuffi-
cient evidence to conclude whether the neurodevelopmental 
impact of prenatal exposure to antipsychotics is dependent 
upon the specific type or class. Findings from clinical stud-
ies of antipsychotic exposure are inconsistent and difficult to 
interpret due to the considerable differences in methodology 
and follow-up period. Several studies reported a delay in 
neurodevelopment among infants with intrauterine exposure 
to antipsychotics. However, these early neurodevelopmental 
delays were frequently transient, having resolved on subse-
quent longitudinal follow-up assessments. The most con-
sistent finding was a transient delay in motor development. 
This was confirmed in our meta-analysis with a relative 
risk of 1.36 for neuromotor deficits after in utero exposure 
to antipsychotics at 6 months of follow-up. However, this 
estimate was based on only two studies. More studies are 
needed to provide a more robust estimate and to study the 
course of motor development over time. Most studies had a 
follow-up period of less than 2 years, for which later-onset 
neurodevelopmental sequelae cannot be excluded. Based on 
the currently available reports, no distinction between the 
various types of antipsychotics can be made as most studies 
combined different types and classes of antipsychotics into 
a single broad category, presumably to increase statistical 
power.
Clinical findings might have been affected by confound-
ing by indication, since most studies compared exposed chil-
dren to non-exposed children of mothers with no history 
of psychiatric illness. Therefore, studies have not been able 
to adequately adjust for genetic predisposition, psychiatric 
illness during pregnancy, or parenting, all of which would 
be expected to independently influence child development 
[110–112]. Regardless of medication exposure, offspring 
of patients with schizophrenia and bipolar disorder have 
an increased risk to develop any mental illness [113] and 
experience more cognitive impairments [114–116]. A recent 
study found impairment of motor function among children 
with a familial risk of schizophrenia [117]. Additionally, 
studies using structural MRI have reported decreased white 
and gray matter volume in offspring of parents with bipo-
lar disorder or schizophrenia [118–121]. It is therefore of 
particular importance for future studies to compare psycho-
tropic medication-exposed children to non-exposed children 
of mothers with similar psychopathology.
Our findings may have been influenced by publication bias, 
since studies without significant results are less likely to be 
published [122]. This is particularly the case for preclinical 
studies. As a result, the rate and severity of neurodevelopmen-
tal deficits presented in this review might be an overestima-
tion. However, the paucity of evidence regarding the long-term 
effects of intrauterine exposure to lithium or antipsychotics 
may also lead to a blunted motivation to invest in studies of 
the potential adverse neurodevelopmental consequences and 
consequent underreporting of associations. Undoubtedly more 
studies of higher quality will be required in order to address 
these questions with greater certainty.
Our results show a discrepancy between findings from 
preclinical and clinical studies, with preclinical studies 
reporting more discernible neurodevelopmental deficits. 
As mentioned above, publication bias might be part of the 
explanation. In addition, many preclinical studies used high 
dosages of medications, exceeding 80% occupancy of the 
D2-receptor causing more side-effects [123]. Lastly, spe-
cies differences cannot be disregarded as a potential source 
of discrepancy between pharmacological studies in animals 
and humans.
High quality clinical studies will be required in order 
to properly assess the risk of adverse neurodevelopmental 
effects of intrauterine exposure to lithium and antipsychot-
ics. Randomized controlled trials are often considered the 
best approach to studying causal inference. However, there is 
broad consensus that randomized assignment for the purpose 
of studying medication side effects is unethical [124]. Fur-
thermore, placebo-controlled randomization of women with 
mental health indications for lithium or antipsychotics is also 
considered unethical when treatment is medically indicated, 
but also regarding exposure of the fetus when treatment is 
not medically indicated. Future studies of neurodevelop-
mental outcome in children with intrauterine exposure to 
psychotropic medication will therefore have to continue to 
rely upon clinical cohort studies, for which non-randomized 
designs can be well suited for studying unintended phar-
macological effects [125]. However, cohort studies should 
ideally have a prospective design with extended follow-up 
periods utilizing validated standardized neurodevelopmental 
outcome measures. Moreover, in an effort to reduce con-
founding by indication, the primary comparison group for 
exposed children should involve non-exposed children of 
mothers with similar psychopathology. Since it is unlikely 
that medicated and non-medicated pregnant women have 
the same disease severity, cohort studies should also con-
sider designs in which pregnant women treated with lithium 
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or antipsychotics are compared to pregnant women with 
the same psychiatric disorder but other pharmacological 
treatments.
The decision for pharmacological treatment during preg-
nancy should always be decided through a patient-centered 
discussion with their healthcare provider by carefully weigh-
ing the risks and benefits of various treatment options and 
by developing an individualised treatment plan.
Conclusion
Prenatal exposure to lithium or antipsychotics has an adverse 
effect on neurodevelopment and behaviour in mice and rats, 
but the precise mechanisms remain unclear. In humans, the 
existence and nature of any effects remains poorly deter-
mined. At present, there is insufficient evidence to estimate 
the neurodevelopmental effects of intrauterine exposure to 
lithium. Although several studies have reported a transient 
neurodevelopmental delay following intrauterine exposure to 
antipsychotics, the current lack of high quality clinical inves-
tigations substantially limits the conclusiveness of the avail-
able evidence. In particular, improved clinical studies will 
require prospective designs with longer follow-up periods 
and more extensive assessments including validated meas-
ures of child development, in order to offer more substanti-
ated evidence-based advice to women with bipolar disorder 
or psychotic disorders regarding the risks and benefits of 
pharmacotherapy during pregnancy.
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